Poseida is developing two approaches with its next-generation CAR-T therapies: autologous and allogeneic.
Autologous therapies are fully customised treatments created using an individuals patient's own T cells.
In contrast, allogeneic therapies use T cells derived from healthy donors, allowing Poseida to make an off-the-shelf treatment for hundreds or thousands of patients from a single manufacturing run.
Poseida's CAR-T products leverage its piggyBac DNA Modification system to engineer therapeutic T cells. Poseida believes this non-viral approach can result in greater safety, efficacy and versatility when treating different forms of cancer. It also enables Poseida to create therapies that are predominantly comprised of stem memory T cells (TSCM cells) which are a younger, self-renewing type of immune cell that may allow for longer duration of response, less toxicity and the ability to successfully treat solid tumours.